Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Corporation Announces Successful Commissioning Of Sepralac® Plant At Carbery Food Ingredients

Union City, CA, September 21, 1999 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) announced the successful start of the first plant in Europe based on its patented Sepralac® Process. The plant was commissioned by Carbery Food Ingredients, of Ireland, pursuant to a license agreement reached between Sepragen and Carbery.

Carbery’s plant will produce, amongst other ingredients, alpha-lactalbumin and lactoferrin which are high value ingredients extracted from cheese whey. These ingredients are being targeted for producing next generation infant formulae that more closely resemble the protein profile of human breast milk, and as health enhancing additives in ‘nutraceutical’ or dietary supplement products. Carbery will also utilize some innovative whey fractions to enhance its existing Isolac range of sportsfood ingredients.

Said John Holland, Operations Director for Carbery, “Carbery Food Ingredients is a technology leader in the manufacture of whey based ingredients and is a well recognized supplier to leading infant formulae producers. The manufacture of this new generation of ingredients will enable us to continue operating at the frontiers of whey technology and give us the ability to better serve our customers with exciting technical innovations. We expect our relationship with Sepragen to grow as we position ourselves as a global supplier of high-end ingredients to both existing and new customers.”

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650